Riyadh – Mubasher: Jamjoom Pharmaceuticals Factory Company (Jamjoom Pharma) posted an annual hike of 77.58% in net profit after Zakat and tax to SAR 247.90 million during the first nine months (9M) of 2023, versus SAR 139.60 million.

The revenues increased by 24.06% year-on-year (YoY) to SAR 893 million in 9M-23 from SAR 719.80 million, according to the interim income statements.

Earnings per share (EPS) reached SAR 3.54 in January-September 2023, compared to SAR 1.99 in 9M-22.

Financial Results for Q3-23

During the third quarter (Q3) of 2023, Jamjoom Pharma registered net profits after Zakat and tax worth SAR 77.20 million, marking a 69.30% leap from SAR 45.60 million in Q3-22.

Revenues stood at SAR 292.60 million in Q3-23, higher by 23.04% YoY than SAR 237.80 million.

On a quarterly basis, the Q3-23 profits dropped by 10.54% from SAR 86.30 million in Q2-23, while the revenues declined by 1.94% from SAR 298.40 million.